华讯
华讯
≡ 导航
网站首页
请拖入内容到容器
华讯
关于我们
请拖入内容到容器
华讯
辞旧迎新,关怀送暖 省市台办领导走访慰问莅临华讯平台
辞旧迎新,关怀送暖 省市台办领导走访慰问莅临华讯平台   在新春佳节来临之际,为进一步增进台胞台商的情感交流,1月19日,江苏省台办副主任吴伟荣一行来到华讯国际知识产权与涉外法律服务平台走访看望台胞台商,市台办副主任李芬琴、联络处处长哈赵刚,江北新区宣传和统战部副部长杨涛,研创园相关负责人陪同参加。   由「南京华讯知识产权顾问有限公司」(以下简称「南京华讯」)副总经理李悦宁女士负责接待各位领导并重点参观了南京华讯及庆辰法律事务所驻南京代表处,期间更关怀企业台胞、员工的春节过年计划,提前致以节日的祝福和亲切的问候。 李悦宁女士汇报了华讯成立历史、团队背景资历、经营情况、典型案例、发展前景等情况,座谈会上,江苏省台办吴副主任了解到在疫情防控常态化及全球经济下行等不利因素影响下,企业的发展情况,嘱咐南京华讯负责人要做好防护工作,保护好自身安全,同时双方还就当下知识产权行业市场现状进行了深入交流。由于,南京华讯于2014年初正式运营。当年度即荣获「江苏省民营科技企业」称号,2016年更获得「江苏省科技型中小企业」称号。南京华讯经营的高阶知识产权信息与顾问服务,在重要科技及医疗产业所涉及的知识产权与涉法项目,均能提供企业所需之资源与解决方案,鉴于,中国与美国是世界上最主要的两大市场,南京华讯更将研究的知识产权着重在中国与美国的专利。并同步扩张到日本与欧洲。南京华讯的重要合作伙伴南京庆辰,更是江苏省与南京市自贸区第一家境外法律事务所,从筹办到取证,南京庆辰得获肯定,有此殊荣。南京华讯与南京庆辰的合作交流,让企业在知识产权议题与涉法项目上,能得到更全方位的专业服务。 南京华讯除了希望为未来进入江苏的台资企业树立榜样,发挥自身为桥梁的作用,更期盼能引导更多台胞人才来江苏投资兴业,为江苏的企业发展奉献一份力。
Details 白箭头 黑箭头
Advanced Version of New Antibiotics-Antimicrobial Peptide
Advanced Version of New Antibiotics-Antimicrobial Peptide   In 1929, British bacteriologist Fleming discovered penicillin for the first time. Since then, Antibiotics have officially entered the stage of history. During the Second World War, penicillin became a very important strategic material to prevent war wounds from being infected. However, with the development of history, more and more antibiotics have sprung up, and the fatal problems (drug resistance) caused by the large-scale application of antibiotics have gradually emerged seriously threatening people's health. Finding new types of antibiotics is an effective way to solve the problem of resistance. Antimicrobial peptide (ABP) originally refers to a class of basic peptides with antibacterial activity induced in insects. The molecular weight is about 2000-7000 and consists of 20-60 amino acid residues. According to its structure, it can be roughly divided into four categories: spiral, sheet, extended and ring. Some ABPs consist entirely of a spiral or sheet, while others have a more complex structure. The characteristic of extended peptides is the lack of recognizable structural motifs. However, they contain large amounts of specific amino acids such as arginine, tryptophan, glycine and histidine. The antibacterial mechanism of traditional antibiotics is that the antibiotics bind to the receptors of specific parts of the pathogen, so that the normal structure of the pathogen is destroyed or some biosynthesis is blocked, in order to achieve antibacterial or bactericidal effects. When the target site of its action changes, the antibiotic will lose its antibacterial effect, which is the main reason why bacteria develop resistance to antibiotics. The most common mechanism of action of ABP is to destroy the membrane potential, change the membrane permeability, and leak metabolites by binding to the cell membrane, directly destroy the pathogen cell membrane and kill bacteria, so it is not easy to develop drug resistance, Moreover, ABP also has the advantages of high antibacterial activity, wide antibacterial spectrum, many types, and a wide range of options, so it is considered to have broad application prospects in the pharmaceutical industry. In addition, a unique feature of many ABPs is their multiple mechanisms of action. For example, the antimicrobial peptide LL-37 that exists in the human body. The most common mechanism of action is to act on bacterial cell membranes, and it can also regulate inflammation and inflammation Anti-inflammatory immune response. The ability of ABP to function through multiple mechanisms and different pathways not only increases its antibacterial activity, but also reduces the tendency to develop drug resistance. Exercising effects through multiple channels can greatly reduce the possibility of bacteria acquiring multiple mutations at the same time, which makes ABP have a good therapeutic potential in drug resistance. In addition, because many ABPs act on the cell membrane sites of bacteria, bacteria must completely redesign their cell membrane structure to undergo mutations, and it takes a long time for multiple mutations to occur. In cancer chemotherapy, it is common to use multiple drugs with different mechanisms to limit the resistance of tumors. However, the use of multiple drugs increases the potential side effects and toxicity of chemotherapy. Therefore, a single ABP drug with multiple complementary mechanisms may have the same antibacterial effect with minimal side effects. Although there are currently a large number of natural ABPs that have excellent therapeutic effects, there are still many potential modifications that can be used to generate new ABPs. The global call for action to develop new antibacterial compounds to avoid the next antibacterial crisis.
Details 白箭头 黑箭头
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis Dingxiangyuan, a leading domestic digital medical and health technology company, announced the launch of a professional-level medical data open platform. This platform is the industry's first open data platform that can fully cover multi-scenario applications such as drugs, diseases, hospitals, departments, diagnosis and treatment, and medical information. It broke the current situation of internal data fragmentation in various institutions in the medical industry. At present, more than 400 pharmaceutical companies, financial insurance companies, and Internet companies including AstraZeneca, Alibaba Cloud, and Huatai Securities have become platform partners. It is reported that the Dingxiangyuan medical data open platform is supported by the core product medication assistant, Insight database, and Dingxiang doctor big data. Relying on 20 years of medical professional-level data accumulation, tens of millions of medical knowledge such as drug diseases, institutional data and tens of thousands of Clove Professional articles produced by the park copyright provide enterprise-level users with open data services based on standardized structured data. In the era of big data, medical care is gradually opening up, but the utilization rate of data within the medical industry is relatively low at this stage. Li Ning, head of product technology at Dingxiangyuan, said that under the premise of ensuring data security, the platform avoids the fragmentation of medical data and facilitates cross-medical organization collaboration, for the development and promotion of new drugs, optimizing clinical treatment plans, and preventing excessive treatment. Provide integrated data hard core support to make medical data play a greater value, thereby saving medical resources. For medical institutions, the Dingxiangyuan Medical Data Open Platform provides prescription review and timely discovery of potential unreasonable drug use problems; for pharmaceutical companies, the medical data open platform provides basic drug data construction; for the financial and insurance industry, the medical data open platform provides risk assessment for pharmaceutical companies , Medical insurance underwriting. In addition, the Dingxiangyuan medical data open platform also provides disease science services, medication instructions query services, and professional physician identity certification. Recently, Dingxiangyuan completed a new financing of US$500 million. With the promotion of the "medical-public" dual-core drive strategy, it is accelerating the accumulation of professional forces on the upstream supply side. The realization of the medical data open platform will also continue to accumulate new data and use the data for internal product innovation, enabling all participants in the medical system to connect and collaborate more closely.
Details 白箭头 黑箭头
最新消息
请拖入内容到容器
重要服务
请拖入内容到容器
华讯
二维码
二维码

地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京      

联系我们
请拖入内容到容器
网站首页
关于我们
最新消息
重要服务
联系我们